Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis

Vaccine

Volumn 29, Issue 34, 2011, Pages 5785-5792

  Beyer, W E P ^a   Nauta, J J P ^b   Palache, A M ^c   Giezeman, K M ^d   Osterhaus, A D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Abbott Established Products Division   (Netherlands)

^c Abbott Healthcare Products   (Netherlands)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Immunogenicity; Influenza; Meta analysis; Safety; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG SAFETY; EVIDENCE BASED PRACTICE CENTER; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS; INFORMATION RETRIEVAL; MEDICAL RECORD; META ANALYSIS; NONHUMAN; ORTHOMYXOVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

EID: 79960555692     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.040     Document Type: Article

References (64)

1. Brandon F.B., Barrett C.D., Hook A.E., Lease G.O. Human febrile response to influenza virus or its ether-isolated haemagglutinins. Proc Soc Exp Biol Med 1967, 125:683.
2. Bachmayer H., Schmidt G., Liehl E. Preparation and properties of a novel influenza subunit vaccine. Postgrad Med J 1976, 52:360-367.
3. Wilschut J. Influenza vaccines: the virosome concept. Immunol Lett 2009, 122:108-111.
4. Ott G., Barchfeld G.L., Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995, 13:1557-1562.
5. Salk J. Reactions to concentrated influenza virus vaccines. J Immunol 1948, 58:369-395.
6. Beyer W.E.P., Palache A.M., Osterhaus A.D.M.E. Comparison of serology and reactogenicity between influenza subunit vaccines and whole or split vaccines. A review and meta-analysis of the literature. Clin Drug Invest 1998, 15:1-12.
7. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Standard 1977, 5:237-247.
8. Nauta J.J.P., Beyer W.E.P., Osterhaus A.D.M.E. On the relationship between antibody response to influenza vaccination, seroprotection and clinical protection from influenza. Biologicals 2009, 37:216-221.
9. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., Song F. Dealing with missing standard deviations of estimates in a meta-analysis. Methods for meta-analysis in medical research 2000, John Wiley & Sons, Chichester, p. 202-203.
10. Beyer W.E.P., Palache A.M., de Jong J.C., Osterhaus A.D.M.E. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002, 20:1340-1353.
11. Beyer W.E.P., Palache A.M., Baljet M., Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989, 7:385-394.
12. Bradburn M.J., Deeks J.J., Berlin J.A., Localio A.R. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26:53-77.
13. Brown H., Prescott R. Applied mixed models in medicine 2006, John Wiley & Sons, Chichester. 2nd ed.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986, 7:177-188.
15. Gross P.A., Ennis F.A., Gaerlan P.F. Comparison of new Triton X-100- and Tween-ether-treated split-product vaccines in children. J Clin Microbiol 1981, 14:534-538.
16. Gross P.A., Quinnan G.V., Gaerlan P.F. Influenza vaccines in children. Comparison of new cetrimonium bromide and standard ether-treated vaccines. Am J Dis Child 1983, 137:26-28.
17. Adlard P., Bryett K. Influenza immunization in children with cystic fibrosis. J Int Med Res 1987, 15:344-351.
18. Hall M.S., Bryett K.A. Influenza vaccination in a boarding school population. Br J Clin Pract 1987, 41:926-929.
19. Ortwein N., Prossler K., Mossner J., Hahn H.L. Influenza vaccination with whole virus, split virus and subunit vaccines in patients with bronchial asthma: Reaction of the respiratory tract, immune response and side effects. Prax Klin Pneumol 1987, 9:614-615.
20. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994, 344:160-163.
21. Bautista Rentero D., Tenías Burillo J.M., Sabater Pons A., Pérez Bermúdez B., Zanón Viguer V. The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens. Rev Esp Salud Publica 1995, 69:463-468.
22. Powers D.C., Hanscome P.J., Pietrobon P.J.F. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine 1995, 13:1330-1335.
23. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997, 15:1675-1679.
24. Powers D.C. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech Ageing Dev 1997, 93:179-188.
25. Schaad U.B., Bühlmann U., Burger R., Ruedeberg A., Wilder-Smith A., Rutishauser M., et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000, 44:1163-1167.
26. Baldo V., Menegon T., Bonello C., Floreani A., Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001, 19:3472-3475.
27. Ben-Yehuda A., Joseph A., Zeira E., Even-Chen S., Louria-Hayon I., Babai I., et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 2003, 69:560-567.
28. Dong P.M., Li Y.Q., Zheng T.Z., Jia Y.P., Li F., Han T.W., et al. Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine. Zhonghua Liu Xing Bing Xue Za Zhi (Chin J Epidemiol) 2003, 24:570-573.
29. Morales A., Salazar J.A., Salazar Y., Garcia A., Arnoux S., Arancibia A., et al. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia. Medicina 2003, 63:197-204.
30. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23:300-306.
31. Ruf B.R., Colberg K., Frick M., Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004, 32:191-198.
32. De Bruijn I.A., Nauta J., Cramer W.C.M., Gerez L., Palache A.M. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005, 23(Suppl. 1):39-49.
33. De Bruijn I.A., Nauta J., Gerez L., Palache A.M. The virosomal influenza vaccine Invivac®: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad®) in elderly subjects. Vaccine 2006, 24:6629-6631.
34. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Mühlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
35. Baldo V., Menegon T., Buoro S., Scalici C., Vesco A., Perale S., et al. Vaccination against influenza in the elderly. Experience with adjuvant vaccines. Ann Ig 1999, 11:369-374.
36. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17:3094-3101.
37. Menegon T., Baldo V., Bonello C., Dalla Costa D., Di Tommaso A., Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999, 15:573-576.
38. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17:99-104.
39. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M., et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001, 17:135-140.
40. Pregliasco F., Mensi C., Serpilli W., Speccher L., Masella P., Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Ag Clin Exp Res 2001, 13:38-43.
41. Frey S., Poland G., Percell S., Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003, 21:4234-4237.
42. Iorio A.M., Francisci D., Camilloni B., Stagni G., De Martino M., Toneatto D., et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003, 21:3629-3637.
43. Squarcione S., Sgricia S., Biasio L.R., Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003, 21:1268-1274.
44. Gabutti G., Guido M., Durando P., De Donno A., Quattrocchi M., Bacilieri S., et al. Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients. J Int Med Res 2005, 33:406-416.
45. Baldo V., Baldovin T., Floreani A., Minuzzo M., Trivello R. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 2006, 21:843-845.
46. Baldo V., Baldovin T., Floreani A., Fragapane E., Trivello R., Angiolelli G., et al. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007, 27:542-547.
47. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Ped Infect Dis J 2009, 28:563-571.
48. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(Suppl. 1):26-38.
49. Banzhoff A., Nacci P., Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontol 2003, 49:177-184.
50. Palache A.M., Beyer W.E.P., Osterhaus A.D.M.E. Influenza vaccine dosages. Vaccine 2008, 26:2305-2306.
51. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 1972, 70:767-777.
52. de Jong J.C., Palache A.M., Beyer W.E.P., Rimmelzwaan G.F., Boon A.C.M., Osterhaus A.D.M.E. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol Standard 2003, 115:63-73.
53. Beyer WEP, Osterhaus ADME. On the seroprotection threshold titer of 40 in HI studies with influenza vaccines. In: The third European influenza conference. Vilamoura, Portugal, 14-17 September 2008. 2008, Abstract 9-001.
54. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010, 10:18. http://www.biomedcentral.com/1471-2288/10/18.
55. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
56. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 2008, 26:6232-6236.
57. Martin J.T. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997, 25:209-213.
58. Iob A., Brianti G., Zamparo E., Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005, 133:687-693.
59. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
60. Fedson D.S. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prevent Med 1994, 23:751-755.
61. World Health and Organization Influenza vaccines. WHO position paper. Wkly Epidemiol Rec 2005, 33:279-287.
62. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vacc 2008, 7:7-10.
63. Beyer W.E.P., Palache A.M., Lüchters G., Nauta J., Osterhaus A.D.M.E. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 2004, 103:125-132.
64. Rubin D.B. Multiple imputation for nonresponse in surveys 1987, John Wiley & Sons, New York.